Relation of Fibrinogen-to-Albumin Ratio to Severity of Coronary Artery Disease and Long-Term Prognosis in Patients with Non-ST Elevation Acute Coronary Syndrome

Table 3

MACE incidences during the follow-up period.

Variable	Group 1 ()	Group 2 ()	Group 3 ()	value
30 days
MACE	9 (2.4%)	19 (5.1%)	27 (7.2%)	0.010
All-cause mortality	0	0	0	—
Myocardial reinfarction	2 (0.5%)	2 (0.5%)	3 (0.8%)	0.875
TVR	7 (1.9%)	18 (4.8%)	25 (6.6%)	0.006
6 months
MACE	17 (4.5%)	36 (9.7%)	45 (12.0%)	0.001
All-cause mortality	1 (0.3%)	2 (0.5%)	1 (0.3%)	0.878
Myocardial reinfarction	2 (0.5%)	6 (1.6%)	11 (2.9%)	0.039
TVR	14 (3.7%)	32 (8.6%)	35 (9.3%)	0.006
1 year
MACE	30 (8.0%)	53 (14.2%)	63 (16.8%)	0.001
All-cause mortality	1 (0.3%)	6 (1.6%)	3 (0.8%)	0.133
Myocardial reinfarction	6 (1.6%)	9 (2.4%)	15 (4.0%)	0.120
TVR	25 (6.7%)	45 (12.1%)	49 (13.0%)	0.010

MACE: major adverse cardiovascular event; TVR: target vessel revascularization.